{"prompt": "['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', '7. EFFICACY, SAFETY, PHARMACOKINETIC, AND', 'HEALTH OUTCOME ASSESSMENTS', '7.1', 'Efficacy Assessments', '7.1.1', 'American College of Rheumatology 20%/50%/70% Response Criteria', 'ACR2O/ACR50/ACR7( will not be calculated by the Investigator during the course of the', 'study, but will be computed in the statistical database for analysis purposes.', 'The number of subjects who achieve an ACR20, ACR50, or ACR70 response at various time', 'points will be calculated. The calculations are based on a 20%, >50%, and >70%', 'improvement from baseline in the SJC assessed in 66 joints and in the TJC assessed in', '68 joints; and a 20%, 50%, and >70% improvement from baseline in at least 3 of the', '5 remaining core set measures:', 'Patient Global Assessment of Disease Activity (VAS)', 'Patient Assessment of Pain (VAS)', 'HAQ-DI', 'Physician Global Assessment (VAS)', 'Level of acute phase reactant (CRP or ESR, using level of CRP in this study)', '7.1.2', '66-68 Joint Assessment', 'The 66-68 joint assessment evaluates 66 joints for swelling and 68 joints for tenderness and', 'pain on motion. The hip joints can be assessed for tenderness, but not for swelling. The', 'following joints are included:', 'Temporomandibular, sternoclavicular, acromioclavicular, shoulders, elbows, wrists,', 'interphalangeal (IP) on digit 1, distal interphalangeals on digits 2 to 5, proximal', 'interphalangeals (PIP) on digits 2 to 5, metacarpophalangeal (MCP) on digits 1 to 5,', 'hips (tenderness only), knees, ankles and tarsus, metatarsals, IP on toe 1, PIP on toes', '2 to 5, and metatarsophalangeals (MTP) on toes 1 to 5.', 'As noted in Table 1, the joint assessor will be independent to the rest of the study team. An', 'independent joint assessor, blinded to other study assessments as well as the dosing regimen,', 'will be identified at each study site to perform the SJC and TJC. To ensure consistent joint', 'evaluation throughout the study, individual subjects should be evaluated by the same joint', 'assessor as in the core studies for all study visits, whenever possible.', 'Amendment 2: 06 March 2019', '90', 'Confidential']['R-Pharm International', 'CL04041024: Clinical Rheumatoid Arthritis Development for Olokizumab (CREDO) 4', 'Olokizumab', 'Artificial, missing, and ankylosed joints are excluded from both tenderness and swelling', 'assessments. If joints are missing or not able to be assessed, the number of joints will be', 'weighted by the actual number of assessable joints, and the missing or not assessable joints', 'should be marked as \"not assessed\" for all subsequent joint assessments for the remainder of', 'the study. If a subject receives IA corticosteroids or IA hyaluronic acid (see Section 6.13.2),', 'any treated joints should be omitted from all subsequent joint assessments and should be', 'rated with their pre-injection status for the remainder of the study.', '7.1.3', 'Patient Global Assessment of Disease Activity (Visual Analog Scale)', 'Subjects will assess the overall disease activity by responding to the following:', 'Considering all the ways in which illness and health conditions may affect you at this', 'time, please make a mark below to show how you are doing, using a 100 mm VAS', 'where 0 is \"very well\" and 100 is \"very poorly\".', '7.1.4', 'Patient Assessment of Pain (Visual Analog Scale)', 'Subjects will rate their short-term arthritis pain by responding to the question:', 'How much pain are you experiencing because of your illness AT THIS TIME? Place a', 'vertical (I) mark on the line to indicate the severity of the pain, using a 100 mm VAS', 'where 0 is \"no pain\" and 100 is \"severe pain\".', '7.1.5', 'Physician Global Assessment (Visual Analog Scale)', 'The Investigator will rate the overall status of the subject for the day of the visit, with respect', 'to RA signs and symptoms and the functional capacity of the subject. The Investigator will', 'respond to the following:', \"Mark an X on the line below to indicate disease activity (independent of the patient's\", 'self-assessment). A 100 mm VAS will be used, where 0 is \"no disease activity\" and', '100 is \"maximal disease activity\".', '7.1.6', 'Disease Activity Score 28-Joint Count (C-Reactive Protein)', 'The DAS28 (CRP) will not be calculated by the Investigator during the course of the study,', 'but will be computed in the statistical database for analysis purposes.', 'The DAS28 (CRP) will be calculated using the SJC (28 joints), TJC (28 joints), CRP level,', 'and the Patient Global Assessment of Disease Activity (VAS) (in mm) according to the', 'following formula:', 'DAS28 (CRP) = 0.56 X N(TJC) + 0.28 X N(SJC) + 0.36 X lognat (CRP + 1) +', '0.014 X Patient Global Assessment of Disease activity (VAS) + 0.96', 'Amendment 2: 06 March 2019', '91', 'Confidential']\n\n###\n\n", "completion": "END"}